Literature DB >> 9811462

Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification.

J G Izzo1, V A Papadimitrakopoulou, X Q Li, H Ibarguen, J S Lee, J Y Ro, A El-Naggar, W K Hong, W N Hittelman.   

Abstract

Cyclin D1 proto-oncogene is a key regulator of the mammalian cell-cycle acting at the restriction point in late G1. Amplification of the cyclin D1 locus, located on chromosome 11q13, as well as cyclin D1 protein overexpression have been reported in several human malignancies. The purpose of this study was to evaluate cyclin D1 gene copy status and protein expression during the multistep process of head and neck tumorigenesis, using a combination of fluorescence in situ hybridization and immunohistochemistry techniques. From 29 selected patients presenting with head and neck squamous carcinoma and whose tumor cytospins had been previously screened for presence (16 cases) or absence (13 cases) of amplification at the 11q13 band, we analysed 46 paraffin-embedded tissue specimens that demonstrated, besides the primary tumor, the presence of contiguous adjacent normal tissue and/or premalignant lesions. Of the 16 amplified cases, nine demonstrated a continuous progression from premalignant to invasive carcinoma and seven (77.7%) of these cases showed cyclin D1 gene amplification in premalignant lesions prior to development of invasive carcinoma. Increased cyclin D1 protein expression was observed in all 16 amplified tumors and five of the 13 (38.4%) non-amplified tumors. Interestingly, dysregulated cyclin D1 expression was also found in the premalignant lesions adjacent to all 16 amplified tumors, and it appeared to precede cyclin D1 gene amplification. In contrast no dysregulated expression was detected in the premalignant lesions of the non-amplified tumors. In conclusion, these findings provide strong evidence for early dysregulation of cyclin D1 expression during the tumorigenesis process and suggest that dysregulated increased expression precedes and possibly enables gene amplification.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811462     DOI: 10.1038/sj.onc.1202153

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

Review 1.  Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma.

Authors:  Giovana R Thomas; Hari Nadiminti; Jacinto Regalado
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

2.  High-resolution mapping identifies a commonly amplified 11q13.3 region containing multiple genes flanked by segmental duplications.

Authors:  Johan H Gibcus; Klaas Kok; Lorian Menkema; Mario A Hermsen; Mirjam Mastik; Philip M Kluin; Jacqueline E van der Wal; Ed Schuuring
Journal:  Hum Genet       Date:  2006-12-15       Impact factor: 4.132

3.  Cyclin D1 overexpression increases susceptibility to 4-nitroquinoline-1-oxide-induced dysplasia and neoplasia in murine squamous oral epithelium.

Authors:  Jonathan F Wilkey; Glenn Buchberger; Kirsten Saucier; Salony M Patel; Ellen Eisenberg; Hiroshi Nakagawa; Carmen Z Michaylira; Anil K Rustgi; Sanjay M Mallya
Journal:  Mol Carcinog       Date:  2009-09       Impact factor: 4.784

4.  Cyclin D1 and cyclin D-dependent kinases enhance oral keratinocyte proliferation but do not block keratinocyte differentiation.

Authors:  Michael Woods; Rima Pant; Sanjay M Mallya
Journal:  Int J Oncol       Date:  2010-12       Impact factor: 5.650

5.  p53: Revealing the Unusual Suspect: a Study and Field Cancerization Minireview.

Authors:  Sandeep S Gupta; Devi Charan Shetty; Aadithya B Urs; Sowmya K
Journal:  Indian J Surg Oncol       Date:  2014-04-19

6.  Growth inhibition and apoptosis by (-)-epicatechin gallate are mediated by cyclin D1 suppression in head and neck squamous carcinoma cells.

Authors:  Young Chang Lim; Seong-Ho Lee; Mee Hyun Song; Kiyoshi Yamaguchi; Joo-Heon Yoon; Eun Chang Choi; Seung Joon Baek
Journal:  Eur J Cancer       Date:  2006-10-12       Impact factor: 9.162

7.  Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy.

Authors:  Björn L D M Brücher; Gisela Keller; Martin Werner; Ulrike Müller; Silke Lassmann; Antonello Domenico Cabras; Falko Fend; Raymonde Busch; Hubert Stein; Hans-Dieter Allescher; Michael Molls; J Rüdiger Siewert; Heinz Höfler; Katja Specht
Journal:  Int J Colorectal Dis       Date:  2008-08-13       Impact factor: 2.571

8.  Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy.

Authors:  Brian J Henson; Samsiddhi Bhattacharjee; Dawn M O'Dee; Eleanor Feingold; Susanne M Gollin
Journal:  Genes Chromosomes Cancer       Date:  2009-07       Impact factor: 5.006

9.  Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.

Authors:  Anne S Tsao; Diane Liu; Jack Martin; Xi-ming Tang; J Jack Lee; Adel K El-Naggar; Ignacio Wistuba; Kirk S Culotta; Li Mao; Ann Gillenwater; Yuko M Sagesaka; Waun K Hong; Vassiliki Papadimitrakopoulou
Journal:  Cancer Prev Res (Phila)       Date:  2009-11

10.  Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene.

Authors:  A M Snijders; B Huey; S T Connelly; R Roy; R C K Jordan; B L Schmidt; D G Albertson
Journal:  Oncogene       Date:  2008-11-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.